Intracranial hemorrhage

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
Tuesday, March 26, 2024
Avicenna, Pulmonary embolism, Brain, Algorithm, Radiology, La Ciotat, NCCT, Pelvis, Radiodensity, Stroke, Abdomen, Mortality, Triage, AI, Aortic dissection, CINA, Deep learning, Google Images, Intracranial hemorrhage, Machine learning, Probability, FDA, Physician, Health, Embolism, Food, Medical imaging

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
Tuesday, March 26, 2024
Avicenna, Pulmonary embolism, Brain, Algorithm, Radiology, La Ciotat, NCCT, Pelvis, Radiodensity, Stroke, Abdomen, Mortality, Triage, AI, Aortic dissection, CINA, Deep learning, Google Images, Intracranial hemorrhage, Machine learning, Probability, FDA, Physician, Health, Embolism, Food, Medical imaging

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

MIVI Neuroscience™ Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference

Retrieved on: 
Thursday, February 8, 2024
Technology, Radiology, Health Technology, Pharmaceutical, Neurology, Other Science, Research, Medical Devices, Infectious Diseases, Hospitals, Clinical Trials, Cardiology, Biotechnology, Health, Practice Management, General Health, Nanotechnology, Science, Medical Supplies, Software, FDA, Surgery, Other Health, Sich, CE marking, Cerebrovascular disease, LVO, NIHSS, Conference, Bangladesh Technical Education Board, Intracranial hemorrhage, Thrombectomy, Safety, Physician, ECASS, Reperfusion, IDE, Thrombus, Patient, Stroke, System, Death

MIVI Neuroscience, Inc. (Eden Prairie, MN) announces the primary endpoint results of its EvaQ Trial, a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q™ Revascularization System for treating acute ischemic stroke.

Key Points: 
  • MIVI Neuroscience, Inc. (Eden Prairie, MN) announces the primary endpoint results of its EvaQ Trial, a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q™ Revascularization System for treating acute ischemic stroke.
  • The data were presented yesterday at the 2024 International Stroke Conference (AZ), a premier event featuring global thought leaders and dedicated to the latest in the science and treatment of cerebrovascular disease and brain health.
  • Results of the EvaQ Trial show the Q Revascularization System to be safe and effective for thrombectomy of Large Vessel Occlusion (LVO) strokes.
  • The primary safety endpoint was symptomatic intracranial hemorrhage (sICH) which was observed at a rate of 6.5%.

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
Wednesday, February 7, 2024
Software, Research, General Health, Technology, Medical Devices, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Shift, CNN, Conference, ISC, Atrial fibrillation, DTG, Neurosurgery, Workflow, FAHA, Diagnosis, ICM, Aneurysm, Intraparenchymal hemorrhage, AI, MLS, Automation, MD, Single Center, Abstract (summary), Stroke, Viz, ICH, Patient, Groin, Triage, Intervention, Artificial intelligence, CSC, UIA, Intracranial hemorrhage, Associate, University of Kentucky, University, McGovern Medical School, Ambient occlusion, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

RapidAI to Enter ISC 2024 Showcasing Extensive Research and Unparalleled Industry Leadership

Retrieved on: 
Tuesday, February 6, 2024
Science, Cardiology, Software, Research, Health, Artificial Intelligence, Health Technology, Technology, Conference, ISC, Critical care, American Heart, Intracranial hemorrhage, Cranial cavity, Ischemia, Hyatt Regency Phoenix, Patient, Multimodality, Implementation, Stroke, Artificial intelligence, Pharmaceutical industry

Through various research presentations, poster abstracts, and learning sessions, RapidAI will highlight how its AI platform is reshaping the industry and driving confident, efficient, and accessible patient care.

Key Points: 
  • Through various research presentations, poster abstracts, and learning sessions, RapidAI will highlight how its AI platform is reshaping the industry and driving confident, efficient, and accessible patient care.
  • “Our commitment to research and finding new, improved ways to enhance patient outcomes is a core pillar for us,” said Dr. David Stoffel, chief business officer of RapidAI.
  • February 7, 6:25 - 6:30 PM MST at Poster Hall, Halls 5-6
    Late-Breaking Science Oral Abstracts IV: Subgroup Analyses From the TIMELESS Trial, Gregory Albers, M.D.
  • Poster Presentation: Acute Ischemic Stroke Patients After Implementation of the RapidAI Platform in a Comprehensive Stroke Center in Santiago, Chile, Pablo Lavados, M.D., presented by Greg Albers, M.D.

New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A

Retrieved on: 
Saturday, December 9, 2023
Research, Infectious Diseases, Baby, Maternity, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Science, Safety, Haemophilia, Pediatrics, Pathology, ASH, University, Risk, World Federation of Hemophilia, HAVEN, Roche, World government, Death, ROG, Pharmacokinetics, Caregiver, Trauma, Phase, Intraparenchymal hemorrhage, Biomarker, Parent, Society, Vein, Life, Intracranial hemorrhage, Pharmaceutical industry, Birth control, Emicizumab, Genentech

Results showed that Hemlibra achieved meaningful bleed control in babies up to 12 months of age and was well tolerated.

Key Points: 
  • Results showed that Hemlibra achieved meaningful bleed control in babies up to 12 months of age and was well tolerated.
  • However, for many babies with hemophilia A, prophylaxis is not started until after the first year of life because of the high treatment burden.
  • Hemlibra, which is already approved and being used to treat babies with hemophilia A, provides a flexible treatment option that can be administered subcutaneously from birth at different dosing frequencies.
  • It is approved for the routine prophylaxis of people with hemophilia A in more than 115 countries worldwide.

Radiology Partners Deploys Clinical AI Across More Than 20 Million Annual Patient Exams

Retrieved on: 
Monday, November 13, 2023
Software, Radiology, Hardware, Oncology, Data Management, Medical Devices, Technology, Hospitals, Artificial Intelligence, Health Technology, Practice Management, Health, Cloud, ICH, Natural language processing, Pulmonary embolism, Organization, RP, IPE, ROI, Teleradiology, Chairperson, Breast cancer, Triage, Patient, Artificial intelligence, NLP, Partner, Workflow, Diagnosis, Partnership, Bone fracture, Hospital, AI, Storage area network, Intracranial hemorrhage, Medical device, Aidoc

By deploying AI across more than 20 million annual exams already this calendar year, RP’s investment in advancing and expanding AI demonstrates its commitment to elevating patient care, enhancing outcomes and improving ROI for clients committed to advancing healthcare.

Key Points: 
  • By deploying AI across more than 20 million annual exams already this calendar year, RP’s investment in advancing and expanding AI demonstrates its commitment to elevating patient care, enhancing outcomes and improving ROI for clients committed to advancing healthcare.
  • Dr. Nina Kottler, RP’s Associate Chief Medical Officer for Clinical AI, emphasized the transformative impact of AI: “Radiologists have long been considered the doctor's doctor.
  • Currently, more than 2,600 of RP’s 3,600 radiologists are using at least one AI tool within their daily workflow.
  • Through this cutting-edge clinical innovation, RP radiologists have enhanced patient care and improved the quality of their output.

University of Miami Health System to Maximize Patient Care with New Aidoc AI Technology

Retrieved on: 
Tuesday, November 14, 2023
Aneurysm, Health, Data management, Research, Pulmonary embolism, EHR, Anatomy, McKinney, Texas, Intracranial hemorrhage, Patient, Algorithm, FDA, Intelligence, Health information management, University, Diagnosis, Pain, AI, Physician, Radiology, Emergency department, Medical device, Aidoc

MIAMI, Nov. 14, 2023 /PRNewswire/ -- University of Miami Health System (UHealth) announced the launch of a system-wide AI deployment across the organization's facilities powered by Aidoc, a pioneer in artificial intelligence. UHealth will have access to Aidoc's AI technology and platform to support the healthcare leader's mission of delivering high-quality, compassionate care by utilizing AI to identify suspected findings early in the care process, coordinate workflows and support continued care beyond diagnosis. 

Key Points: 
  • MIAMI, Nov. 14, 2023 /PRNewswire/ -- University of Miami Health System (UHealth) announced the launch of a system-wide AI deployment across the organization's facilities powered by Aidoc, a pioneer in artificial intelligence.
  • UHealth will have access to Aidoc's AI technology and platform to support the healthcare leader's mission of delivering high-quality, compassionate care by utilizing AI to identify suspected findings early in the care process, coordinate workflows and support continued care beyond diagnosis.
  • Moreover, the aiOS™ is highly adaptable, ensuring that UHealth can scale and evolve its AI capabilities in response to the evolving needs of patient care.
  • UHealth and Aidoc share a steadfast commitment to innovation and research and are dedicated to exploring new frontiers in AI applications to enhance the patient experience.

Texas County Memorial Hospital Goes Live with RapidAI to Enhance Neurovascular Decision Making and Rural Stroke Care

Retrieved on: 
Tuesday, October 24, 2023
Cardiology, Software, General Health, Health, Artificial Intelligence, Hospitals, Health Technology, Technology, CTP, Stroke, ICH, Intracranial hemorrhage, Physician, LVO, Texas County, CTA, Trauma, Artificial intelligence, Social services, Geographic Locator Codes, Partnership, Hospital, CT, MO, Patient, Death, RCAT, Missouri Department of Social Services, Medical imaging, Nursing

To support the implementation of RapidAI, TCMH received a grant from the Rural Citizens Access to Telehealth (RCAT) project.

Key Points: 
  • To support the implementation of RapidAI, TCMH received a grant from the Rural Citizens Access to Telehealth (RCAT) project.
  • Rural counties in Missouri have a statistically significantly higher stroke death rate than both the state and urban counties.
  • “We are incredibly excited to have RapidAI in our hospital and expect it will enhance care delivery significantly and improve outcomes for our stroke patients – expediting our door-to-decision time by saving valuable minutes in assessing and triaging stroke patients,” said Jason Mayberry, the Stroke Coordinator at Texas County Memorial Hospital.
  • “RapidAI will revolutionize how we provide stroke care at TCMH and ensure members of our community have access to the best possible care, regardless of where they live.”
    With RapidAI, stroke and trauma teams at TCMH and other rural or spoke hospitals can streamline decision making and expedite patient care.

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Annual general meeting, Constipation, JCO, Fatal, Arrhythmia, Joint Planning and Development Office, NYSE, Lung cancer, Food, Cetuximab, Myocardial infarction, Memorial Sloan Kettering Cancer Center, IRC, Plasma, Vomiting, NSCLC, Bleeding, Cough, Anemia, BRAF, Pfizer, ORR, Inc., Society, American Society of Clinical Oncology, Mutation, CRC, Disease, Diarrhea, Abdominal pain, Visual impairment, DSM-IV codes, Nausea, Rash, Periodic breathing, Journal, Fatigue, DOR, Pneumonia, Intracranial hemorrhage, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, MSK, ASCO, Pleural effusion, Edema, Patient, PFE, Risk, Pharmaceutical industry

“Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer.

Key Points: 
  • “Today’s approval builds on our long-standing commitment to deliver innovative, personalized medicines to patients with lung cancer.
  • “The PHAROS trial demonstrated that these patients could benefit from BRAFTOVI + MEKTOVI targeted therapy regardless of their prior treatment history.
  • BRAFTOVI + MEKTOVI is also FDA-approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • BRAFTOVI is FDA-approved, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.